Core Insights - The company reported a 5.4% organic constant currency sales growth in Q4 2025, marking the fifth consecutive year of mid-single-digit growth or above [2][15][37] - The U.S. business grew by 5.7%, driven by new product momentum and strong robotic sales, while international sales increased by 5% [2][16] - The company is undergoing a significant transformation of its U.S. sales force, aiming for a dedicated and specialized team to enhance productivity and growth [6][8][72] Financial Performance - For the fiscal year 2025, the company achieved net sales of $2.244 billion, a 10.9% increase on a reported basis, and an adjusted EPS of $2.42, up 4.8% year-over-year [15][16][17] - Free cash flow for the year was $1.172 billion, growing over 11% year-over-year, marking the third consecutive year of high single-digit free cash flow growth [19][20] - The adjusted gross margin was reported at 72.4%, higher than the previous year, while the adjusted operating margin was 29.1% [18][19] Strategic Initiatives - The company is focusing on three key strategic priorities: people and culture, operational excellence, and innovation and diversification [8][10][11] - A significant emphasis is placed on enhancing the U.S. sales channel to drive consistent growth, with expectations for the majority of the transition to be completed by 2027 [6][8][72] - The introduction of new products, including the "magnificent seven" platform, is expected to change the standard of care and drive future growth [11][12][72] Market Outlook - The company anticipates organic constant currency revenue growth for 2026 in the low single-digit range (1% to 3%) and adjusted EPS of $8.30 to $8.45 [7][20] - The guidance reflects potential disruptions from the U.S. sales force transition, ongoing international market evolution, and pricing erosion [20][21] - The company expects to prioritize returning capital to shareholders through buybacks, with a plan for up to $1.5 billion in buybacks approved by the board [76]